AI-generated · cited to primary sources · not investment advice
Beta Drugs Ltd (BETA) Nov 2024 Filing Analysis
Does management do what it says?
The company reported that the CDMO business is projected to maintain a steady growth rate of 5% to 10% annually, and the current year highlights indicate healthy growth in domestic and international business which includes CDMO partners. (1 met across 1 tracked commitment)
“So on overall basis, we expect a growth of 7% to 10% here.”
Imatinib Oral Solution (Admine-OS) is featured in the current presentation as a key NDDS formulation being worked on, though the specific launch completion is not explicitly confirmed as 'launched' in the FY25 highlights list. (1 in progress, 2 met, 1 revised across 4 tracked commitments)
“Set to launch new NDDS formulations in H2’25 Imatinib Oral Solution 80mg/ml”
The company is working on First-to-Launch (FFTL) products for release in FY24/25.
“Working on FFTLs to be launched in FY’24”
R&D expenditure is expected to increase from the current 2-3% to 4-5% of revenue after the new facility is established. — target: 4% to 5% (+1 more commitment)
“So, the R&D expense right now may be around 2% to 3%, but it will eventually go up to 4% to 5% after coming up with this facility.”
See the full cited Management analysis of Beta Drugs Ltd
Where does growth come from?
The company is deepening its penetration into institutional segments, adding over 200 new prescribers in the first half of the year to reach a total of 1,500+. (4 steady, 1 accelerating across 5 signals)
“As on today we have total of 1500 plus prescribers from our range of products... We have added more than 200 plus prescribers in our H125. We have further penetrated deeply into the private, corporate and government hospitals.”
See the full cited Future Growth analysis of Beta Drugs Ltd
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.